We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600  Open access books available
177,000  International authors and editors
195M  Downloads

154  Countries delivered to
TOP 1%  Our authors are among the most cited scientists
12.2%  Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

The innate immune system provides a tactical response, signaling the presence of ‘non-self’ organisms and activating B cells to produce antibodies to bind to the intruders’ epitopic sites. The antibodies identify targets for scavenging cells that engulf and consume the microbes, reducing them to non-functioning units (Stengel et al., 2002b). The antibodies also stimulate the production of cytokines, complement factors and acute-phase response proteins that either damage an intruder’s plasma membrane directly or trigger the second phase of immune response. The innate immune system protects against many extracellular bacteria or free viruses found in blood plasma, lymph, tissue fluid, or interstitial space between cells, but it cannot clean out microbes that burrow into cells, such as viruses, intracellular bacteria, and protozoa (Janeway, 2005; Lydyard et al., 2000; Stengel et al., 2002b). The innate immune system is a complex system and the obscure relationships between the immune system and the environment in which several modulatory stimuli are embedded (e.g. antigens, molecules of various origin, physical stimuli, stress stimuli). This environment is noisy because of the great amount of such signals. The immune noise has therefore at least two components: (a) the internal noise, due to the exchange of a network of molecular and cellular signals belonging to the immune system during an immune response or in the homeostasis of the immune system. The concept of the internal noise might be viewed in biological terms as a status of sub-inflammation required by the immune response to occur; (b) the external noise, the set of external signals that target the immune system (and hence that add noise to the internal one) during the whole life of an organism.

For clinical treatment of infection, several available methods focus on killing the invading microbes, neutralizing their response, and providing palliative or healing care to other organs of the body. Few biological or chemical agents have just one single effect; for example, an agent that kills a virus may also damage healthy ‘self’ cells. A critical function of drug discovery and development is to identify new compounds that have maximum intended efficacy with minimal side effects on the general population. These examples include antibiotics as microbe killers; interferons as microbe neutralizers; interleukins, antigens from killed (i.e. non-toxic) pathogens, and pre-formed and monoclonal antibodies as immunity enhancers (each of very different nature); and anti-inflammatory and anti-histamine compounds as palliative drugs (Stengel et al., 2002b).

Recently, several models of immune response to infection (Asachenkov, 1994; Nowak & May, 2000; Perelson & Weisbuch, 1997; Rundell et al., 1995) with emphasis on the human-
immunodeficiency virus have been reported (Nowak et al., 1995; Perelson et al., 1993; Perelson et al., 1996; Stafford et al., 2000). Norbert Wiener (Wiener, 1948) and Richard Bellman (Bellman, 1983) appreciated and anticipated the application of mathematical analysis for treatment in a broad sense, and Swan made surveys on early optimal control applications to biomedical problems (Swan, 1981). Kirschner (Kirschner et al., 1997) offers an optimal control approach to HIV treatment, and intuitive control approaches are presented in (Bonhoeffer et al., 1997; De Boer & Boucher, 1996; Wein et al., 1998; Wodarz & Nowak, 1999, 2000).

The dynamics of drug response (pharmacokinetics) are modeled in several works (Robinson, 1986; van Rossum et al., 1986) and control theory is applied to drug delivery in other studies (Bell & Katusiime, 1980; Carson et al., 1985; Chizeck & Katona, 1985; Gentilini et al., 2001; Jelliffe, 1986; Kwong et al., 1995; Parker et al., 1996; Polycarpou & Conway, 1995; Schumitzky, 1986). Recently, Stengel (Stengel et al., 2002a) presented a simple model for the response of the innate immune system to infection and therapy, reviewed the prior method and results of optimization, and introduced a significant extension to the optimal control of enhancing the immune response by solving a two-point boundary-value problem via an iterative method. Their results show that not only the progression from an initially life-threatening state to a controlled or cured condition but also the optimal history of therapeutic agents that produces that condition. In their study, the therapeutic method is extended by adding linear-optimal feedback control to the nominal optimal solution. However, the performance of quadratic optimal control for immune systems may be decayed by the continuous exogenous pathogen input, which is considered as an environmental disturbance of the immune system. Further, some overshoots may occur in the optimal control process and may lead to organ failure because the quadratic optimal control only minimizes a quadratic cost function that is only the integration of squares of states and allows the existence of overshoot (Zhou et al., 1996).

Recently, a minimax control scheme of innate immune system is proposed by the dynamic game theory approach to treat the robust control with unknown disturbance and initial condition (Chen et al., 2008). They consider unknown disturbance and initial condition as a player who wants to destroy the immune system and a control scheme as another player to protect the innate immune system against the disturbance and uncertain initial condition. However, they assume that all state variables are available. It is not the case in practical application.

In this study, a robust $H_\infty$ tracking control of immune response is proposed for therapeutic enhancement to track a desired immune response under stochastic exogenous pathogen input, environmental disturbances and uncertain initial states. Furthermore, the state variables may not be all available and the measurement is corrupted by noises too. Therefore, a state observer is employed for state estimation before state feedback control of stochastic immune systems. Since the statistics of these stochastic factors may be unknown or unavailable, the $H_\infty$ observer-based control methodology is employed for robust $H_\infty$ tracking design of stochastic immune systems. In order to attenuate the stochastic effects of stochastic factors on the tracking error, their effects should be considered in the stochastic $H_\infty$ tracking control procedure from the robust design perspective. The effect of all possible stochastic factors on the tracking error to a desired immune response, which is generated by a desired model, should be controlled below a prescribed level for the enhanced immune systems, i.e. the proposed robust $H_\infty$ tracking control need to be designed from the stochastic $H_\infty$ tracking perspective. Since the stochastic innate immune system is highly
nonlinear, it is not easy to solve the robust observer-based tracking control problem by the stochastic nonlinear $H_\infty$ tracking method directly. Recently, fuzzy systems have been employed to efficiently approximate nonlinear dynamic systems to efficiently treat the nonlinear control problem (Chen et al., 1999, 2000; Li et al., 2004; Lian et al., 2001). A fuzzy model is proposed to interpolate several linearized stochastic immune systems at different operating points to approximate the nonlinear stochastic innate immune system via smooth fuzzy membership functions. Then, with the help of fuzzy approximation method, a fuzzy $H_\infty$ tracking scheme is developed so that the $H_\infty$ tracking control of stochastic nonlinear immune systems could be easily solved by interpolating a set of linear $H_\infty$ tracking systems, which can be solved by a constrained optimization scheme via the linear matrix inequality (LMI) technique (Boyd, 1994) with the help of Robust Control Toolbox in Matlab (Balas et al., 2007). Since the fuzzy dynamic model can approximate any nonlinear stochastic dynamic system, the proposed $H_\infty$ tracking method via fuzzy approximation can be applied to the robust control design of any model of nonlinear stochastic immune system that can be T-S fuzzy interpolated. Finally, a computational simulation example is given to illustrate the design procedure and to confirm the efficiency and efficacy of the proposed $H_\infty$ tracking control method for stochastic immune systems under external disturbances and measurement noises.

2. Model of innate immune response

A simple four-nonlinear, ordinary differential equation for the dynamic model of infectious disease is introduced here to describe the rates of change of pathogen, immune cell and antibody concentrations and as an indicator of organic health (Asachenkov, 1994; Stengel et al., 2002a). In general, the innate immune system is corrupted by environmental noises. Further, some state variable cannot be measured directly and the state measurement may be corrupted by measurement noises. A more general dynamic model will be given in the sequel.

$$
\begin{align*}
\dot{x}_1 &= (a_{11} - a_{12}x_3)x_1 + b_1u_1 + w_1 \\
\dot{x}_2 &= a_{21}(x_4)a_{22}x_3x_3 - a_{23}(x_2 - x_1^2) + b_2u_2 + w_2 \\
\dot{x}_3 &= a_{31}x_2 - (a_{32} + a_{33}x_1)x_3 + b_3u_3 + w_3 \\
\dot{x}_4 &= a_{41}x_1 - a_{42}x_4 + b_4u_4 + w_4 \\
y_1 &= c_1x_2 + n_1, y_2 = c_2x_3 + n_2, y_3 = c_3x_4 + n_3 \\
a_{23}(x_4) &= \begin{cases} 
\cos(\pi x_4), & 0 \leq x_4 \leq 0.5 \\
0, & 0.5 \leq x_4
\end{cases}
\end{align*}
$$

(1)

where $x_1$ denotes the concentration of a pathogen that expresses a specific foreign antigen; $x_2$ denotes the concentration of immune cells that are specific to the foreign antigen; $x_3$ denotes the concentration of antibodies that bind to the foreign antigen; $x_4$ denotes the characteristic of a damaged organ [$x_4=0$: healthy, $x_4 \geq 1$: dead]. The combined therapeutic control agents and the exogenous inputs are described as follows: $u_1$ denotes the pathogen killer’s agent; $u_2$ denotes the immune cell enhancer; $u_3$ denotes the antibody enhancer; $u_4$ denotes the organ healing factor (or health enhancer); $w_1$ denotes the rate of continuing introduction of exogenous pathogens; $w_1 \sim w_4$ denote the environmental disturbances or unmodeled errors and residues; $w_1 \sim w_4$ are zero mean white noises, whose covariances are uncertain or

www.intechopen.com
unavailable; and \( a_2(x_4) \) is a nonlinear function that describes the mediation of immune cell generation by the damaged cell organ. And if there is no antigen, then the immune cell maintains the steady equilibrium value of \( x_2^* \). The parameters have been chosen to produce a system that recovers naturally from the pathogen infections (without treatment) as a function of initial conditions during a period of times. Here, \( y_1, y_2, y_3 \) are the measurements of the corresponding states; \( c_1, c_2, c_3 \) are the measurement scales; and \( n_1, n_2, n_3 \) are the measurement noises. In this study, we assume the measurement of pathogen \( x_1 \) is unavailable. For the benchmark example in (1), both parameters and time units are abstractions, as no specific disease is addressed. The state and control are always positive because concentrations cannot go below zero, and organ death is indicated when \( x_4 \geq 1 \). The structural relationship of system variables in (1) is illustrated in Fig. 1. Organ health mediates immune cell production, inferring a relationship between immune response and fitness of the individual. Antibodies bind to the attacking antigens, thereby killing pathogenic microbes directly, activating complement proteins, or triggering an attack by phagocytic cells, e.g. macrophages and neutrophils. Each element of the state is subject to an independent control, and new microbes may continue to enter the system. In reality, however, the concentration of invaded pathogens is hardly to be measured. We assume that only the rest of three elements can be measured with measurement noises by medical devices or other biological techniques such as an immunofluorescence microscope, which is a technique based on the ability of antibodies to recognize and bind to specific molecules. It is then possible to detect the number of molecules easily by using a fluorescence microscope (Piston, 1999).

Fig. 1. Innate and enhanced immune response to a pathogenic attack under exogenous pathogens, environmental disturbances, and measurement noises.
Several typical uncontrolled responses to increasing levels of initial pathogen concentration under sub-clinical, clinical, chronic, and lethal conditions have been discussed and shown in Fig. 2 (Stengel et al., 2002a). In general, the sub-clinical response would not require medical examination, while the clinical case warrants medical consultation but is self-healing without intervention. Pathogen concentration stabilizes at non-zero values in the chronic case, which is characterized by permanently degraded organ health, and pathogen concentration diverges without treatment in the lethal case and kills the organ (Stengel et al., 2002b). Finally, a more general disease dynamic model for immune response could be represented as

\[
\dot{x}(t) = f(x(t)) + g(x(t))u(t) + Dw(t), \quad x(0) = x_0
\]

\[
y(t) = c(x(t)) + n(t)
\]

where \( x(t) \in \mathbb{R}^{n_x} \) is the state vector; \( u(t) \in \mathbb{R}^{m_u} \) is the control agent; \( w(t) \in \mathbb{R}^{n_w} \) includes exogenous pathogens, environmental disturbances or model uncertainty. \( y(t) \in \mathbb{R}^{n_y} \) is the measurement output; and \( n(t) \in \mathbb{R}^{n_n} \) is the measurement noises. We assume that \( w(t) \) and \( n(t) \) are independent stochastic noises, whose covariances may be uncertain or unavailable. All possible nonlinear interactions in the immune system are represented by \( f(x(t)) \).

Fig. 2. Native immune responses to attack by different pathogens which are sub-clinical, clinical, chronic, and lethal conditions (Stengel et al., 2002a).
3. Robust H∞ Therapeutic Control of Stochastic Innate Immune Response

Our control design purpose for nonlinear stochastic innate immune system in (2) is to specify a state feedback control \( u(t) = k(x(t) - x_d(t)) \) so that the immune system can track the desired response \( x_d(t) \). Since the state variables are unavailable for feedback tracking control, the state variables have to be estimated for feedback tracking control \( u(t) = k(\hat{x}(t) - x_d(t)) \). Suppose the following observer-based control with \( y(t) \) as input and \( u(t) \) as output is proposed for robust H∞ tracking control.

\[
\dot{x}(t) = f(\hat{x}(t)) + g(\hat{x}(t))u(t) + l(\hat{x}(t))(y(t) - c(\hat{x}(t)))
\]

\[
u(t) = k(\hat{x}(t) - x_d(t))
\]

(3)

where the observer-gain \( l(\hat{x}(t)) \) is to be specified so that the estimation error \( e(t) = x(t) - \hat{x}(t) \) can be as small as possible and control gain \( k(\hat{x}(t) - x_d(t)) \) is to be specified so that the system states \( x(t) \) can come close to the desired state responses \( x_d(t) \) from the stochastic point of view.

Consider a reference model of immune system with a desired time response described as

\[
\dot{x}_d(t) = A_d x_d(t) + r(t)
\]

(4)

where \( x_d(t) \in \mathbb{R}^{n_x} \) is the reference state vector; \( A_d \in \mathbb{R}^{n_x \times n_x} \) is a specific asymptotically stable matrix and \( r(t) \) is a desired reference signal. It is assumed that \( x_d(t), \forall t > 0 \) represents a desired immune response for nonlinear stochastic immune system in (2) to follow, i.e. the therapeutic control is to specify the observer-based control in (3) such that the tracking error \( \hat{x}(t) = x(t) - x_d(t) \) must be as small as possible under the influence of uncertain exogenous pathogens and environmental disturbances \( w(t) \) and measurement noises \( n(t) \). Since the measurement noises \( n(t) \), the exogenous pathogens and environmental disturbances \( w(t) \) are uncertain and the reference signal \( r(t) \) could be arbitrarily assigned, the robust H∞ tracking control design in (3) should be specified so that the stochastic effect of three uncertainties \( w(t) \), \( n(t) \) and \( r(t) \) on the tracking error could be set below a prescribed value \( \rho^2 \), i.e. both the stochastic H∞ reference tracking and H∞ state estimation should be achieved simultaneously under uncertain \( w(t) \), \( n(t) \) and \( r(t) \).

\[
\frac{\mathbb{E}\left[\int_0^t (\hat{x}^T(t)Q_1\hat{x}(t) + e^T(t)Q_2e(t))dt\right]}{\mathbb{E}\left[\int_0^t (w^T(t)w(t) + n^T(t)n(t) + r^T(t)r(t))dt\right]} \leq \rho^2
\]

(5)

where the weighting matrices \( Q_1 \) are assumed to be diagonal as follows

\[
Q_1 = \begin{bmatrix}
q_{11} & 0 & 0 & 0 \\
0 & q_{22} & 0 & 0 \\
0 & 0 & q_{33} & 0 \\
0 & 0 & 0 & q_{44}
\end{bmatrix}, \quad i = 1, 2.
\]

The diagonal element \( q_{ij} \) of \( Q_1 \) denotes the punishment on the corresponding tracking error and estimation error. Since the stochastic effect of \( w(t) \), \( r(t) \) and \( n(t) \) on tracking error \( \hat{x}(t) \)
and estimation error $e(t)$ is prescribed below a desired attenuation level $\rho^2$ from the energy point of view, the robust $H_\infty$ stochastic tracking problem of equation (5) is suitable for the robust $H_\infty$ stochastic tracking problem under environmental disturbances $w(t)$, measurement noises $n(t)$ and changeable reference $r(t)$, which are always met in practical design cases.

**Remark 1:**

If the environmental disturbances $w(t)$ and measurement noises $n(t)$ are deterministic signals, the expectative symbol $E[\cdot]$ in (5) can be omitted.

Let us denote the augmented vector $\bar{x} = \begin{bmatrix} e(t) \\ x(t) \\ x_d(t) \end{bmatrix}$, then we get the dynamic equation of the augmented stochastic system as

$$
\begin{aligned}
\dot{\bar{x}}(t) &= 
\begin{bmatrix}
\dot{e}(t) \\
\dot{x}(t) \\
\dot{x}_d(t)
\end{bmatrix} \\
&= 
\begin{bmatrix}
f(x) - f(\hat{x}) + k(\hat{x} - x_d)(g(x) - g(\hat{x})) + l(\hat{x})(c(x) - c(\hat{x})) \\
f(x) + k(\hat{x} - x_d)g(x) \\
A_d x_d
\end{bmatrix} \\
&+ 
\begin{bmatrix}
I & 0 & 0 \\
0 & D & 0 \\
0 & 0 & I
\end{bmatrix}
\begin{bmatrix}
n(t) \\
w(t) \\
r(t)
\end{bmatrix}
\end{aligned}
$$

(6)

The robust $H_\infty$ stochastic tracking performance in (5) can be represented by

$$
E \left[ \int_0^T \bar{x}^T(t) \bar{x}(t) dt \right] \leq \rho^2 E \left[ \int_0^T V(x(0)) dt \right]
$$

or

$$
E \left[ \int_0^T \bar{x}^T(t) \bar{x}(t) dt \right] \leq \rho^2 E \left[ \int_0^T \bar{w}^T(t) \bar{w}(t) dt \right]
$$

where $\bar{w} = \begin{bmatrix} Q_d & 0 & 0 \\
0 & Q_1 & -Q_1 \\
0 & 0 & Q_1 \end{bmatrix}$.

If the stochastic initial condition $x(0) \neq 0$ and is also considered in the $H_\infty$ tracking performance, then the above stochastic $H_\infty$ inequality should be modified as

$$
E \left[ \int_0^T \bar{x}^T(t) \bar{x}(t) dt \right] \leq E \left[ V(x(0)) \right] + \rho^2 E \left[ \int_0^T \bar{w}^T(t) \bar{w}(t) dt \right]
$$

(9)
for some positive function $V(\bar{x}(0))$. Then we get the following result.

**Theorem 1:** If we can specify the control gain $k(\hat{x} - x_d)$ and observer gain $l(\hat{x})$ in the observer-based control law in (3) for stochastic immune system (2) such that the following HJI has a positive solution $V(\bar{x}(t)) > 0$

$$\bar{x}(t)^T \bar{Q}(t) + \left( \frac{\partial V(\bar{x}(t))}{\partial \bar{x}(t)} \right)^T F(\bar{x}(t)) + \frac{1}{4\rho^2} \left( \frac{\partial V(\bar{x}(t))}{\partial \bar{x}(t)} \right)^T D\bar{P} \left( \frac{\partial V(\bar{x}(t))}{\partial \bar{x}(t)} \right) < 0 \quad (10)$$

Then the robust stochastic $H_\infty$ tracking performance in (5) is achieved for a prescribed tracking performance $\rho^2$.

Proof: see Appendix A.

Since $\rho^2$ is a prescribed noise attenuation level of $H_\infty$ tracking performance in (5), based on the analysis above, the optimal stochastic $H_\infty$ tracking performance still need to minimize $\rho^2$ as follows

$$\rho_0^2 = \min_{V(\bar{x}(t)) > 0} \rho^2 \quad (11)$$

subject to $V(\bar{x}(t)) > 0$ and equation (10).

At present, there does not exist any analytic or numerical solution for (10) or (11) except in very simple cases.

4. Robust fuzzy observer-based tracking control design for stochastic innate immune system

Because it is very difficult to solve the nonlinear HJI in (10), no simple approach is available to solve the constrained optimization problem in (11) for robust model tracking control of stochastic innate immune system. Recently, the fuzzy T-S model has been widely applied to approximate the nonlinear system via interpolating several linearized systems at different operating points (Chen et al., 1999,2000; Takagi & Sugeno, 1985). Using fuzzy interpolation approach, the HJI in (10) can be replaced by a set of linear matrix inequalities (LMIs). In this situation, the nonlinear stochastic $H_\infty$ tracking problem in (5) could be easily solved by fuzzy method for the design of robust $H_\infty$ tracking control for stochastic innate immune response systems.

Suppose the nonlinear stochastic immune system in (1) can be represented by the Takagi-Sugeno (T-S) fuzzy model (Takagi & Sugeno, 1985). The T-S fuzzy model is a piecewise interpolation of several linearized models through membership functions. The fuzzy model is described by fuzzy If-Then rules and will be employed to deal with the nonlinear $H_\infty$ tracking problem by fuzzy observer-based control to achieve a desired immune response under stochastic noises. The $i$-th rule of fuzzy model for nonlinear stochastic immune system in (1) is in the following form (Chen et al., 1999,2000).

**Plant Rule $i$:**

If $z_i(t)$ is $F_{i1}$ and ... and $z_g(t)$ is $F_{ig}$,

then $\dot{x}(t) = A_i x(t) + B_i u(t) + D\omega(t), \quad i = 1, 2, 3, \ldots, L$

$$y(t) = C_i x(t) + n(t) \quad (12)$$
in which $F_{ij}$ is the fuzzy set; $A_i$, $B_i$, and $C_i$ are known constant matrices; $L$ is the number of If-Then rules; $g$ is the number of premise variables; and $z_1(t), z_2(t), \ldots, z_g(t)$ are the premise variables. The fuzzy system is inferred as follows (Chen et al., 1999,2000; Takagi & Sugeno, 1985)

$$\hat{x}(t) = \frac{\sum_{i=1}^{L} \mu_i(z(t)) [A_i x(t) + B_i u(t) + D w(t)]}{\sum_{i=1}^{L} \mu_i(z(t))}$$

$$y = \sum_{i=1}^{L} h_i(z(t)) C_i x(t) + n(t)$$

(13)

where $\mu_i(z(t)) = \prod_{j=1}^{g} F_{ij}(z_j(t))$, $h_i(z(t)) = \frac{\mu_i(z(t))}{\sum_{i=1}^{L} \mu_i(z(t))}$, $z(t) = \{z_1(t), z_2(t), \ldots, z_g(t)\}$, and $F_{ij}(z_j(t))$ is the grade of membership of $z_j(t)$ in $F_{ij}$.

We assume

$$\mu_i(z(t)) \geq 0 \text{ and } \sum_{i=1}^{L} \mu_i(z(t)) > 0$$

(14)

Therefore, we get

$$h_i(z(t)) \geq 0 \text{ and } \sum_{i=1}^{L} h_i(z(t)) = 1$$

(15)

The T-S fuzzy model in (13) is to interpolate $L$ stochastic linear systems to approximate the nonlinear system in (1) via the fuzzy basis functions $h_i(z(t))$. We could specify the parameter $A_i$ and $B_i$ easily so that $\sum_{i=1}^{L} h_i(z(t)) A_i x(t)$ and $\sum_{i=1}^{L} h_i(z(t)) B_i$ in (13) can approximate $F(x(t))$ and $g(x(t))$ in (2) by the fuzzy identification method (Takagi & Sugeno, 1985).

By using fuzzy If-Then rules interpolation, the fuzzy observer is proposed to deal with the state estimation of nonlinear stochastic immune system (1).

**Observer Rule i:**

If $z_i(t)$ is $F_{i1}$ and ... and $z_g(t)$ is $F_{ig}$,

then

$$\dot{\hat{x}}(t) = A_i \hat{x}(t) + B_i \hat{u}(t) + L_i (y(t) - \hat{y}(t)), \quad i = 1, 2, 3, \ldots, L$$

(16)

where $L_i$ is the observer gain for the $i$th observer rule and $\hat{y}(t) = \sum_{i=1}^{L} h_i(z(t)) C_i \hat{x}(t)$.

The overall fuzzy observer in (16) can be represented as (Chen et al., 1999,2000)

$$\dot{\hat{x}}(t) = \sum_{i=1}^{L} h_i(z(t))[A_i \hat{x}(t) + B_i \hat{u}(t) + L_i (y(t) - \hat{y}(t))]$$

(17)
Suppose the following fuzzy observer-based controller is employed to deal with the above robust $H_\infty$ tracking control design:

**Control Rule j:**

If $z_j(t)$ is $F_{j1}$ and ... and $z_g(t)$ is $F_{ji_g}$,

then $u = \sum_{j=1}^{l} h_j(z(t)) K_j(\hat{x}(t) - x_d(t))$ \hspace{1cm} (18)

**Remark 2:**

1. The premise variables $z(t)$ can be measurable stable variables, outputs or combination of measurable state variables (Ma et al., 1998; Tanaka et al., 1998; Wang et al., 1996). The limitation of this approach is that some state variables must be measurable to construct the fuzzy observer and fuzzy controller. This is a common limitation for control system design of T–S fuzzy approach (Ma et al., 1998; Tanaka et al., 1998). If the premise variables of the fuzzy observer depend on the estimated state variables, i.e., $\hat{z}(t)$ instead of $z(t)$ in the fuzzy observer, the situation becomes more complicated. In this case, it is difficult to directly find control gains $K_i$ and observer gains $L_i$. The problem has been discussed in (Tanaka et al., 1998).

2. The problem of constructing T–S fuzzy model for nonlinear systems can be found in (Kim et al., 1997; Sugeno & Kang, 1988).

Let us denote the estimation errors as $e(t) = x(t) - \hat{x}(t)$. The estimation errors dynamic is represented as

\[ \dot{e}(t) = \hat{x}(t) - \dot{\hat{x}}(t) \]

\[ = L \sum_{j=1}^{j} \sum_{i=1}^{i} h_j(z(t)) h_i(z(t)) \left[ A_i x(t) + B_i u(t) + D w(t) \right] - \left[ A_j \dot{\hat{x}}(t) + B_j u(t) + L_j y(t) - C_j \dot{\hat{x}}(t) \right] \]

After manipulation, the augmented system in (6) can be expressed as the following fuzzy approximation form

\[ \tilde{x}(t) = \sum_{j=1}^{j} h_j(z(t)) \sum_{i=1}^{i} h_i(z(t)) \left[ \tilde{A}_{ij} \tilde{x}(t) + \tilde{E}_{ij} \tilde{r}(t) \right] \] \hspace{1cm} (19)

where $\tilde{A}_{ij} = \left[ A_i - L_i C_j \right] - B_j K_j A_i + B_j K_j \left[ B_i K_j \right]$, $\tilde{x}(t) = \left[ e(t) \hspace{1cm} x(t) \hspace{1cm} n(t) \right]$, $\tilde{r}(t) = \left[ w(t) \hspace{1cm} r(t) \right]$, $\tilde{E}_{ij} = \left[ 0 \hspace{1cm} 0 \hspace{1cm} 0 \right]$.

**Theorem 2:** In the nonlinear stochastic immune system of (2), if $\mathcal{P} = \mathcal{P}^T > 0$ is the common solution of the following matrix inequalities:

\[ \tilde{A}_{ij}^P + \tilde{P} \tilde{A}_{ij} + \frac{1}{\rho^2} \tilde{P} \tilde{E}_{ij} \tilde{P} + \tilde{Q} < 0 , \quad i, j = 1, 2, \ldots, L \] \hspace{1cm} (20)

then the robust $H_\infty$ tracking control performance in (8) or (9) is guaranteed for a prescribed $\rho^2$. 

www.intechopen.com
In the above robust H∞ tracking control design, we don’t need the statistics of disturbances, measurement noises and initial condition. We only need to eliminate their effect on the tracking error and state estimation error below a prescribed level $\rho^2$. To obtain the best H∞ tracking performance, the optimal H∞ tracking control problem can be formulated as the following minimization problem.

$$
\rho_0^2 = \min_{\mathcal{P} > 0} \rho^2
$$

subject to $\mathcal{P} > 0$ and equation (20).

Proof: see Appendix B.

In general, it is not easy to analytically determine the constrained optimization problem in (21). Fortunately, the optimal H∞ tracking control problem in (21) can be transferred into a minimization problem subject to some linear matrix inequalities (LMIs). The LMIP can be solved by a computationally efficient method using a convex optimization technique (Boyd, 1994) as described in the following.

By the Schur complements (Boyd, 1994), equation (20) is equivalent to

$$
\begin{bmatrix}
\bar{A}_j^T\bar{P} + \bar{P}\bar{A}_j + \bar{Q} \\
\mathcal{L}^T\mathcal{P}
\end{bmatrix} < 0
$$

(22)

where $\mathcal{L} = \begin{bmatrix} L_i & I & 0 \\
0 & I & 0 \\
0 & 0 & I \end{bmatrix}$ and $H = \begin{bmatrix} -I & 0 & 0 \\
0 & D & 0 \\
0 & 0 & I \end{bmatrix}$.

For the convenience of design, we assume $\bar{P} = \begin{bmatrix} P_{11} & 0 & 0 \\
0 & P_{22} & 0 \\
0 & 0 & P_{33} \end{bmatrix}$ and substitute it into (22) to obtain

$$
\begin{bmatrix}
S_{11} & S_{12} & 0 & Z_i & P_{11} & 0 \\
S_{21} & S_{22} & S_{23} & 0 & P_{22} & 0 \\
0 & S_{32} & S_{33} & 0 & 0 & P_{33} \\
Z_i^T & 0 & 0 & -\rho^2 I & 0 & 0 \\
P_{11} & P_{22} & 0 & 0 & -\rho^2(DD^T)^{-1} & 0 \\
0 & 0 & P_{33} & 0 & 0 & -\rho^2 I
\end{bmatrix} < 0
$$

(23)

where

$S_{11} = A_i^TP_{11} + P_{11}A_i - C_i^TZ_i - Z_iC_i + Q_2$

$S_{12} = S_{21} = -P_{22}B_iK_j$

$S_{22} = (A_i + B_iK_j)^TP_{22} + P_{22}(A_i + B_iK_j) + Q_1$

$S_{23} = S_{32} = -P_{22}B_iK_j - Q_1$

$S_{33} = A_i^TP_{33} + P_{33}A_d + Q_1$ and $Z_i = P_{11}L_i$. 

www.intechopen.com
Since five parameters $P_{11}$, $P_{22}$, $P_{33}$, $K_j$, and $L_i$ should be determined from (23) and they are highly coupled, there are no effective algorithms for solving them simultaneously till now. In the following, a decoupled method (Tseng, 2008) is provided to solve these parameters simultaneously.

Note that (23) can be decoupled as

$$
\begin{bmatrix}
S_{11} & S_{12} & 0 & Z_i & P_{11} & 0 \\
S_{21} & S_{22} & S_{23} & 0 & P_{22} & 0 \\
0 & S_{32} & S_{33} & 0 & 0 & P_{33} \\
Z_i^T & 0 & 0 & -p^2I & 0 & 0 \\
P_{11} & P_{22} & 0 & 0 & -p^2(DD)^{-1} & 0 \\
0 & 0 & P_{33} & 0 & 0 & -p^2I \\
\end{bmatrix}
$$

(24)

where $\gamma$ and $\gamma_1$ are some positive scalars.

**Lemma 1:**

If

$$
\begin{bmatrix}
a_{11} & 0 & 0 & a_{14} & a_{15} & 0 \\
0 & a_{22} & a_{23} & 0 & 0 & 0 \\
0 & a_{32} & a_{33} & 0 & 0 & a_{36} \\
a_{41} & 0 & 0 & a_{44} & 0 & 0 \\
a_{51} & 0 & 0 & 0 & a_{55} & 0 \\
0 & 0 & a_{63} & 0 & 0 & a_{66} \\
\end{bmatrix}
< 0
$$

(25)
and

\[
\begin{bmatrix}
 b_{11} & b_{12} & 0 & 0 \\
 b_{21} & b_{22} & b_{23} & b_{24} \\
 0 & b_{32} & b_{33} & 0 \\
 0 & b_{42} & 0 & b_{44}
\end{bmatrix} < 0
\] (26)

then

\[
\begin{bmatrix}
 a_{11} & 0 & 0 & a_{14} & a_{15} & 0 \\
 0 & a_{22} & a_{23} & 0 & 0 & 0 \\
 0 & a_{32} & a_{33} & 0 & 0 & a_{36} \\
 a_{41} & 0 & 0 & a_{44} & 0 & 0 \\
 a_{51} & 0 & 0 & 0 & a_{55} & 0 \\
 0 & 0 & a_{63} & 0 & 0 & a_{66}
\end{bmatrix}
\begin{bmatrix}
 b_{11} & b_{12} & 0 & 0 & 0 & 0 \\
 b_{21} & b_{22} & b_{23} & b_{24} & 0 & 0 \\
 0 & b_{32} & b_{33} & 0 & 0 & 0 \\
 0 & 0 & 0 & 0 & 0 & 0 \\
 0 & 0 & b_{42} & 0 & b_{44} & 0 \\
 0 & 0 & 0 & 0 & 0 & 0
\end{bmatrix} < 0
\] (27)

Proof: see Appendix C.

From the above lemma, it is obvious that if

\[
\begin{bmatrix}
 A_i^T P_{11} + P_{11} A_i - C_i^T Z_i^T \ Z_i C_j + Q_2 + \gamma P_{22} \\
 0 & -\gamma_1 I + Q_1 \\
 0 & 0 & A_j^T P_{33} + P_{33} A_j + Q_1 + \gamma P_{22} \\
 Z^T & 0 & 0 & -\rho^2 I \\
 P_{11} & 0 & 0 & 0 & -\rho^2 (D D^T)^{-1} \\
 0 & 0 & P_{33} & 0 & 0
\end{bmatrix} < 0
\] (28)

and

\[
\begin{bmatrix}
 -\gamma P_{22} & -P_{22} B_i K_j \\
 (-P_{22} B_i K_j)^T (A_j + B_i K_j) P_{22} & -P_{22} B_i K_j + P_{22} (A_i + B_i K_j) + \gamma I \\
 0 & -\gamma P_{22} \\
 0 & P_{22} \\
 0 & -\gamma P_{22}
\end{bmatrix} < 0
\] (29)

then (23) holds.

Remark 3:

Note that (28) is related to the observer part (i.e., the parameters are \( P_{11}, P_{22}, P_{33}, \) and \( L_i \)) and (29) is related to the controller part (i.e., the parameters are \( P_{22} \) and \( K_i \)), respectively. Although the parameters \( P_{22}, K_i \) and \( \gamma \) are coupled nonlinearly, seven parameters \( P_{11}, P_{22}, P_{33}, K_i, L_i, \gamma \) and \( \gamma_1 \) can be determined by the following arrangement.

www.intechopen.com
Note that, by the Schur complements (Boyd, 1994) equation (28) is equivalent to

\[
\begin{bmatrix}
A^T_{11}P_{11} + P_{11}A - C^T Z^T - Z C + Q_2 & 0 & 0 & Z_1 \\
0 & -\gamma I + Q_1 & -Q_1 & 0 \\
0 & -Q_1 & A^T_{33}P_{33} + P_{33}A_d + Q_1 & 0 \\
Z_1^T & 0 & 0 & -\rho^2 I \\
P_{11} & 0 & 0 & 0 \\
0 & 0 & 0 & P_{33} \\
I & 0 & 0 & 0 \\
0 & 0 & I & 0 \\
0 & 0 & 0 & 0 \\
\end{bmatrix}
\]  

(30)

where \( W_{22} = P_{22}^\frac{3}{2} \), and equation (29) is equivalent to

\[
\begin{bmatrix}
-\gamma W_{22} & -B_j Y_j \\
(-B_j Y_j)^T W_{22} A^T_{11} + A^T_{11} W_{22} + Y_j B^T_j + B_j Y_j & -\gamma W_{22} \\
0 & (-B_j Y_j)^T W_{22} \\
0 & W_{22} \\
0 & W_{22} \\
\end{bmatrix}
\begin{bmatrix}
0 & 0 & 0 & 0 \\
0 & 0 & -\gamma W_{22} & 0 \\
0 & -\gamma W_{22} & 0 & -\gamma I \\
0 & -\gamma W_{22} & 0 & -\gamma I \\
\end{bmatrix}
\]  

< 0

(31)

where \( Y_j = K_j W_{22} \).

Therefore, if (30) and (31) are all held then (23) holds. Recall that the attenuation \( \rho^2 \) can be minimized so that the optimal H\(_\infty\) tracking performance in (21) is reduced to the following constrained optimization problem.

\[
\rho_0^2 = \min_{P_{11}, P_{22}, P_{33}} \rho^2
\]

subject to \( P_{11} > 0, P_{22} > 0, P_{33} > 0, \gamma > 0, \gamma_1 > 0 \) and (30)-(31).

which can be solved by decreasing \( \rho^2 \) as small as possible until the parameters \( P_{11} > 0, P_{22} > 0, P_{33} > 0, \gamma > 0 \) and \( \gamma_1 > 0 \) do not exist.
Remark 4:
Note that the optimal $H_\infty$ tracking control problem in (32) is not a strict LMI problem since it is still a bilinear form in (30)-(31) of two scalars $\gamma$ and $\gamma_1$ and becomes a standard linear matrix inequality problem (LMIP) (Boyd, 1994) if $\gamma$ and $\gamma_1$ are given in advance. The decoupled method (Tseng, 2008) bring some conservatism in controller design. However, the parameters $P_{11} = W_{22}^{-1}$, $P_{33}$, $K_j = Y_j W_{22}^{-1}$ and $L_i = P_{11}^{-1} Z_i$ can be determined simultaneously from (32) by the decoupled method if scalars $\gamma$ and $\gamma_1$ are given in advance. The useful software packages such as Robust Control Toolbox in Matlab (Balas et al., 2007) can be employed to solve the LMIP in (32) easily.

In general, it is quite easy to determine scalars $\gamma$ and $\gamma_1$ beforehand to solve the LMIP with a smaller attenuation level $\rho^2$. In this study, the genetic algorithm (GA) is proposed to deal with the optimal $H_\infty$ tracking control problem in (32) since GA, which can simultaneously evaluate many points in the parameters space, is a very powerful searching algorithm based on the mechanics of natural selection and natural genetics. More details about GA can be found in (Jang et al., 1997).

According to the analysis above, the $H_\infty$ tracking control of stochastic innate immune system via fuzzy observer-based state feedback is summarized as follows and the structural diagram of robust fuzzy observer-based tracking control design has shown in Fig. 3.

Desired immune response $\dot{x}_d = A_dx_d + r$

Solving LMIs

Fuzzy observer-based controller $u = \sum h_i(z)K_j(\hat{x} - x_i)$

T-S fuzzy model $\dot{x} = \sum h_i[A_i\dot{x} + B_iu + D_iw]$

Fuzzy observer $\dot{x} = \sum h_i[A_i\dot{x} + B_iu + L_i(y - \hat{y})]$

Solving LMIs

Nonlinear immune system $\dot{x} = f(x) + g(x)u + Dw$

Fig. 3. Structural diagram of robust fuzzy observer-based tracking control design.
**Design Procedure:**
1. Provide a desired reference model in (4) of the immune system.
2. Select membership functions and construct fuzzy plant rules in (12).
3. Generate randomly a population of binary strings: With the binary coding method, the scalars $\gamma$ and $\gamma_1$ would be coded as binary strings. Then solve the LMIP in (32) with scalars $\gamma$ and $\gamma_1$ corresponding to binary string using Robust Control Toolbox in Matlab by searching the minimal value of $\rho^2$. If the LMIP is infeasible for the corresponding string, this string is escaped from the current generation.
4. Calculate the fitness value for each passed string: In this step, the fitness value is calculated based on the attenuation level $\rho^2$.
5. Create offspring strings to form a new generation by some simple GA operators like reproduction, crossover, and mutation: In this step, (i) strings are selected in a mating pool from the passed strings with probabilities proportional to their fitness values, (ii) and then crossover process is applied with a probability equal to a prescribed crossover rate, (iii) and finally mutation process is applied with a probability equal to a prescribed mutation rate. Repeating (i) to (iii) until enough strings are generated to form the next generation.
6. Repeat Step 3 to Step 5 for several generations until a stop criterion is met.
7. Based on the scalars $\gamma$ and $\gamma_1$ obtained from above steps, one can obtain the attenuation level $\rho^2$ and the corresponding $P_{11}, P_{22} = W_{22}^{-1}, P_{33}, K_j = Y_j W_{22}^{-1}$ and $L_1 = P_{11}^{-1}Z_j$, simultaneously.
8. Construct the fuzzy observer in (17) and fuzzy controller in (18).

### 5. Computational simulation example

| Parameter | Value | Description |
|-----------|-------|-------------|
| $a_{11}$  | 1     | Pathogens reproduction rate coefficient |
| $a_{12}$  | 1     | The suppression by pathogens coefficient |
| $a_{12}$  | 3     | Immune reactivity coefficient |
| $a_{23}$  | 1     | The mean immune cell production rate coefficient |
| $x_2$     | 2     | The steady-state concentration of immune cells |
| $a_{31}$  | 1     | Antibodies production rate coefficient |
| $a_{32}$  | 1.5   | The antibody mortality coefficient |
| $a_{33}$  | 0.5   | The rate of antibodies suppress pathogens |
| $a_{41}$  | 0.5   | The organ damage depends on the pathogens damage possibilities coefficient |
| $a_{42}$  | 1     | Organ recovery rate |
| $b_1$     | -1    | Pathogen killer’s agent coefficient |
| $b_2$     | 1     | Immune cell enhancer coefficient |
| $b_3$     | 1     | Antibody enhancer coefficient |
| $b_4$     | -1    | Organ health enhancer coefficient |
| $c_1$     | 1     | Immune cell measurement coefficient |
| $c_2$     | 1     | Antibody measurement coefficient |
| $c_3$     | 1     | Organ health measurement coefficient |

Table 1. Model parameters of innate immune system (Marchuk, 1983; Stengel et al., 2002b).
We consider the nonlinear stochastic innate immune system in (1), which is shown in Fig. 1. The values of the parameters are shown in Table 1. The stochastic noises of immune systems are mainly due to measurement errors, modeling errors and process noises (Milutinovic & De Boer, 2007). The rate of continuing introduction of exogenous pathogen and environmental disturbances \( w_1 \sim w_4 \) are unknown but bounded signals. Under infectious situation, the microbes infect the organ not only by an initial concentration of pathogen at the beginning but also by the continuous exogenous pathogens invasion \( w_1 \) and other environmental disturbances \( w_2 \sim w_4 \). In reality, however, the concentration of invaded pathogens is hardly to be measured. So, we assume that only immune cell, antibody, and organ health can be measured with measurement noises by medical devices or other biological techniques (e.g. immunofluorescence microscope). And then we can detect the numbers of molecules easily by using a fluorescence microscope (Piston, 1999).

The dynamic model of stochastic innate immune system under uncertain initial states, environmental disturbances and measurement noises is controlled by a combined therapeutic control as

\[
\begin{align*}
\dot{x}_1 &= (1 - x_3)x_1 - u_1 + w_1 \\
\dot{x}_2 &= 3a_{22}(x_4)x_1 x_3 - (x_2^2 - 2) u_2 + w_2 \\
\dot{x}_3 &= x_2 - (1.5 + 0.5x_1)x_3 + u_3 + w_3 \\
\dot{x}_4 &= 0.5x_1 - x_4 + u_4 + w_4 \\
y_1 &= x_2 + n_1, y_2 = x_3 + n_2, y_3 = x_4 + n_3 \\
a_{21}(x_4) &= \begin{cases} 
\cos(\pi x_4), & 0 \leq x_4 \leq 0.5 \\
0, & 0.5 \leq x_4
\end{cases}
\end{align*}
\]  

A set of initial condition is assumed \( x(0) = [3.5 \ 2 \ 1.33 \ 0]^T \). For the convenience of simulation, we assume that \( w_1 \sim w_4 \) are zero mean white noises with standard deviations being all equal to 2. The measurement noises \( n_1 \sim n_3 \) are zero mean white noises with standard deviations being equal to 0.1. In this example, therapeutic controls \( u_1 \sim u_4 \) are combined to enhance the immune system. The measurable state variables \( y_1 \sim y_3 \) with measurement noises by medical devices or biological techniques are shown in Fig. 4. Our reference model design objective is that the system matrix \( A_d \) and \( r(t) \) should be specified beforehand so that its transient responses and steady state of reference system for stochastic innate immune response system are desired. If the real parts of eigenvalues of \( A_d \) are more negative (i.e. more robust stable), the tracking system will be more robust to the environmental disturbances. After some numerical simulations for clinical treatment, the desired reference signals are obtained by the following reference model, which is shown in Fig. 5.

\[
x_d(t) = \begin{bmatrix} 
-1.1 & 0 & 0 & 0 \\
0 & -2 & 0 & 0 \\
0 & 0 & -4 & 0 \\
0 & 0 & 0 & -1.5
\end{bmatrix} x_d(t) + B_d u_{\text{step}}(t)
\]  

where \( B_d = [0 \ 4 \ 16/3 \ 0]^T \) and \( u_{\text{step}}(t) \) is the unit step function. The initial condition is given by \( x_d(0) = [2.5 \ 3 \ 1.1 \ 0.8]^T \).

www.intechopen.com
Fig. 4. The measurable state variables \( y_1 \sim y_3 \) with measurement noises \( n_1 \sim n_3 \) by medical devices or biological technique.

Fig. 5. The desired reference model with four desired states in (34): pathogens \( (x_{d1}, \text{blue, dashed square line}) \), immune cells \( (x_{d2}, \text{green, dashed triangle line}) \), antibodies \( (x_{d3}, \text{red, dashed diamond line}) \), and organ \( (x_{d4}, \text{magenta, dashed, circle line}) \).

We consider the lethal case of uncontrolled stochastic immune system in Fig. 6. The pathogen concentration increases rapidly causing organ failure. We aim at curing the organ before the organ health index exceeds one after a period of pathogens infection. As shown in Fig. 6, the black dashed line is a proper time to administer drugs.
Fig. 6. The uncontrolled stochastic immune responses (lethal case) in (33) are shown to increase the level of pathogen concentration at the beginning of the time period. In this case, we try to administrate a treatment after a short period of pathogens infection. The cutting line (black dashed line) is an optimal time point to give drugs. The organ will survive or fail based on the organ health threshold (horizontal dotted line) \[x_4<1: \text{survival}, \ x_4>1: \text{failure}\].

To minimize the design effort and complexity for this nonlinear innate immune system in (33), we employ the T-S fuzzy model to construct fuzzy rules to approximate nonlinear immune system with the measurement output \[y_3\] and \[y_4\] as premise variables.

**Plant Rule i:**

If \[y_3\] is \(F_{i1}\) and \[y_4\] is \(F_{i2}\), then

\[
\dot{x}(t) = A_i x(t) + B_a(t) + D u(t), \ i = 1,2,3,\ldots,L
\]

\[
y(t) = C x(t) + n(t)
\]

To construct the fuzzy model, we must find the operating points of innate immune response. Suppose the operating points for \[y_3\] are at \(\bar{y}_{31} = 0.333\), \(\bar{y}_{32} = 1.667\), and \(\bar{y}_{33} = 3.667\). Similarly, the operating points for \[y_4\] are at \(\bar{y}_{41} = 0\), \(\bar{y}_{42} = 1\), and \(\bar{y}_{43} = 2\). For the convenience, we can create three triangle-type membership functions for the two premise variables as in Fig. 7 at the operating points and the number of fuzzy rules is \(L = 9\).

Then, we can find the fuzzy linear model parameters \(A_i\) in the Appendix D as well as other parameters \(B\), \(C\) and \(D\). In order to accomplish the robust H\(_\infty\) tracking performance, we should adjust a set of weighting matrices \(Q_1\) and \(Q_2\) in (8) or (9) as

\[
Q_1 = \begin{bmatrix}
0.01 & 0 & 0 & 0 \\
0 & 0.01 & 0 & 0 \\
0 & 0 & 0.01 & 0 \\
0 & 0 & 0 & 0.01
\end{bmatrix}, \quad Q_2 = \begin{bmatrix}
0.01 & 0 & 0 & 0 \\
0 & 0.01 & 0 & 0 \\
0 & 0 & 0.01 & 0 \\
0 & 0 & 0 & 0.01
\end{bmatrix}.
\]

After specifying the desired reference model, we need to solve the constrained optimization problem in (32) by employing Matlab Robust Control Toolbox. Finally, we obtain the feasible parameters \(\gamma = 40\) and \(\gamma_1 = 0.02\), and a minimum attenuation level \(\rho_0 = 0.93\) and a
common positive-definite symmetric matrix $\bar{P}$ with diagonal matrices $P_{11}$, $P_{22}$ and $P_{33}$ as follows:

$$
\begin{align*}
P_{11} &= \begin{bmatrix}
0.23193 & -1.5549e-4 & 0.083357 & -0.2704 \\
-1.5549e-4 & 0.010373 & -1.4534e-3 & -7.0637e-3 \\
0.083357 & -1.4534e-3 & 0.33365 & 0.24439 \\
-0.2704 & -7.0637e-3 & 0.24439 & 0.76177
\end{bmatrix} \\
P_{22} &= \begin{bmatrix}
0.0023082 & 9.4449e-6 & -5.7416e-5 & -5.0375e-6 \\
9.4449e-6 & 0.0016734 & 2.4164e-5 & -1.8316e-6 \\
-5.7416e-5 & 2.4164e-5 & 0.0015303 & 5.8989e-6 \\
-5.0375e-6 & -1.8316e-6 & 5.8989e-6 & 0.0015453
\end{bmatrix} \\
P_{33} &= \begin{bmatrix}
1.0671 & -1.0849e-5 & 3.4209e-5 & 5.9619e-6 \\
-1.0849e-5 & 1.9466 & -1.4584e-5 & 1.9167e-6 \\
3.4209e-5 & -1.4584e-5 & 3.8941 & -3.2938e-6 \\
5.9619e-6 & 1.9167e-6 & -3.2938e-6 & 1.4591
\end{bmatrix}
\end{align*}
$$

The control gain $K_j$ and the observer gain $L_i$ can also be solved in the Appendix D.

Fig. 7. Membership functions for two premise variables $y_3$ and $y_4$.

Figures 8-9 present the robust H$_\infty$ tracking control of stochastic immune system under the continuous exogenous pathogens, environmental disturbances and measurement noises. Figure 8 shows the responses of the uncontrolled stochastic immune system under the initial concentrations of the pathogens infection. After the one time unit (the black dashed line), we try to provide a treatment by the robust H$_\infty$ tracking control of pathogens infection. It is seen that the stochastic immune system approaches to the desired reference model quickly. From the simulation results, the tracking performance of the robust model tracking control via T-S fuzzy interpolation is quite satisfactory except for pathogens state $x_1$ because the pathogens concentration cannot be measured. But, after treatment for a specific period, the pathogens are still under control. Figure 9 shows the four combined therapeutic control agents. The performance of robust H$_\infty$ tracking control is estimated as

$$
\frac{\mathbb{E} \left[ \int_0^T (\bar{x}^T(t)Q\bar{x}(t) + e^T(t)Qe(t))dt \right]}{\mathbb{E} \left[ \int_0^T (w^T(t)w(t) + n^T(t)n(t) + r^T(t)r(t))dt \right]} \approx 0.033 \lesssim \rho^2 = 0.93
$$
Robust $H_\infty$ tracking control of stochastic innate immune system under noises. We try to administrate a treatment after a short period (one time unit) of pathogens infection then the stochastic immune system approach to the desired reference model quickly except for pathogens state $x_1$.

Fig. 8. The robust $H_\infty$ tracking control of stochastic immune system under the continuous exogenous pathogens, environmental disturbances and measurement noises.

Fig. 9. The robust $H_\infty$ tracking control in the simulation example. The drug control agents $u_1$ (blue, solid square line) for pathogens, $u_2$ for immune cells (green, solid triangle line), $u_3$ for antibodies (red, solid diamond line) and $u_4$ for organ (magenta, solid circle line).

Obviously, the robust $H_\infty$ tracking performance is satisfied. The conservative results are due to the inherent conservation of solving LMI in (30)-(32).
6. Discussion and conclusion

In this study, we have developed a robust $H_\infty$ tracking control design of stochastic immune response for therapeutic enhancement to track a prescribed immune response under uncertain initial states, environmental disturbances and measurement noises. Although the mathematical model of stochastic innate immune system is taken from the literature, it still needs to compare quantitatively with empirical evidence in practical application. For practical implementation, accurate biodynamic models are required for treatment application. However, model identification is not the topic of this paper. Furthermore, we assume that not all state variables can be measured. In the measurement process, the measured states are corrupted by noises. In this study, the statistic of disturbances, measurement noises and initial condition are assumed unavailable and cannot be used for the optimal stochastic tracking design. Therefore, the proposed $H_\infty$ observer design is employed to attenuate these measurement noises to robustly estimate the state variables for therapeutic control and $H_\infty$ control design is employed to attenuate disturbances to robustly track the desired time response of stochastic immune system simultaneously. Since the proposed $H_\infty$ observer-based tracking control design can provide an efficient way to create a real time therapeutic regime despite disturbances, measurement noises and initial condition to protect suspected patients from the pathogens infection, in the future, we will focus on applications of robust $H_\infty$ observer-based control design to therapy and drug design incorporating nanotechnology and metabolic engineering scheme. Robustness is a significant property that allows for the stochastic innate immune system to maintain its function despite exogenous pathogens, environmental disturbances, system uncertainties and measurement noises. In general, the robust $H_\infty$ observer-based tracking control design for stochastic innate immune system needs to solve a complex nonlinear Hamilton-Jacobi inequality (HJI), which is generally difficult to solve for this control design. Based on the proposed fuzzy interpolation approach, the design of nonlinear robust $H_\infty$ observer-based tracking control problem for stochastic innate immune system is transformed to solve a set of equivalent linear $H_\infty$ observer-based tracking problem. Such transformation can then provide an easier approach by solving an LMI-constrained optimization problem for robust $H_\infty$ observer-based tracking control design. With the help of the Robust Control Toolbox in Matlab instead of the HJI, we could solve these problems for robust $H_\infty$ observer-based tracking control of stochastic innate immune system more efficiently. From the in silico simulation examples, the proposed robust $H_\infty$ observer-based tracking control of stochastic immune system could track the prescribed reference time response robustly, which may lead to potential application in therapeutic drug design for a desired immune response during an infection episode.

7. Appendix

7.1 Appendix A: Proof of Theorem 1

Before the proof of Theorem 1, the following lemma is necessary.

Lemma 2:

For all vectors $\alpha, \beta \in \mathbb{R}^{m \times 1}$, the following inequality always holds

$$\alpha^T \beta + \beta^T \alpha \leq \frac{1}{\rho} \alpha^T \alpha + \rho^2 \beta^T \beta$$

for any scale value $\rho > 0$.

Let us denote a Lyapunov energy function $V(\mathbf{X}(t)) > 0$. Consider the following equivalent equation:
\[
E \left[ \int_0^T \tau^T(t) \tilde{Q}(t) \tau(t) dt \right] = E[V(\tau(0))] - E[V(\tau(\infty))] + E \left[ \int_0^T \left( \tau^T(t) \tilde{Q}(t) + \frac{dV(\tau(t))}{dt} \right) dt \right] 
\]  
(A1)

By the chain rule, we get
\[
\frac{dV(\tau(t))}{dt} = \left( \frac{\partial V(\tau(t))}{\partial \tau(t)} \right)^T \tilde{D}(t) \frac{d\tau(t)}{dt} + \frac{1}{2} \frac{\partial V(\tau(t))}{\partial \tau(t)} \tilde{D}(t) \tilde{D}(t)^T \frac{\partial V(\tau(t))}{\partial \tau(t)}
\]  
(A2)

Substituting the above equation into (A1), by the fact that \( V(\tau(\infty)) \geq 0 \), we get
\[
E \left[ \int_0^T \tau^T(t) \tilde{Q}(t) \tau(t) dt \right] \leq E[V(\tau(0))] + E \left[ \int_0^T \left( \tau^T(t) \tilde{Q}(t) + \frac{\partial V(\tau(t))}{\partial \tau(t)} \right)^T F(\tau(t)) + \frac{1}{4} \frac{\partial V(\tau(t))}{\partial \tau(t)} \right] dt 
\]  
(A3)

By Lemma 2, we have
\[
\left( \frac{\partial V(\tau(t))}{\partial \tau(t)} \right)^T \tilde{D}(t) \frac{d\tau(t)}{dt} + \frac{1}{2} \frac{\partial V(\tau(t))}{\partial \tau(t)} \tilde{D}(t) \tilde{D}(t)^T \frac{\partial V(\tau(t))}{\partial \tau(t)} 
\]  
\[
\leq \frac{1}{4\rho^2} \left( \frac{\partial V(\tau(t))}{\partial \tau(t)} \right)^T \tilde{D}(t) \tilde{D}(t)^T + \rho^2 \tau^T(t) \tilde{P}(t) \tau(t)
\]  
(A4)

Therefore, we can obtain
\[
E \left[ \int_0^T \tau^T(t) \tilde{Q}(t) \tau(t) dt \right] \leq E[V(\tau(0))] + E \left[ \int_0^T \left( \tau^T(t) \tilde{Q}(t) + \frac{\partial V(\tau(t))}{\partial \tau(t)} \right)^T F(\tau(t)) + \frac{1}{4} \frac{\partial V(\tau(t))}{\partial \tau(t)} \right] dt 
\]  
(A5)

By the inequality in (10), then we get
\[
E \left[ \int_0^T \tau^T(t) \tilde{Q}(t) \tau(t) dt \right] \leq E[V(\tau(0))] + \rho^2 E \left[ \int_0^T \tau^T(t) \tilde{D}(t) \tilde{D}(t)^T + \frac{1}{4} \frac{\partial V(\tau(t))}{\partial \tau(t)} \right] dt 
\]  
(A6)

If \( \tau(0) = 0 \), then we get the inequality in (8).

7.2 Appendix B: Proof of Theorem 2
Let us choose a Lyapunov energy function \( V(\tau(t)) = \tau^T(t) \tilde{P}(t) \tau(t) > 0 \) where \( \tilde{P} = \tilde{P}^T > 0 \). Then equation (A1) is equivalent to the following:
\[
E \left[ \int_0^T \tau^T(t) \tilde{Q}(t) \tau(t) dt \right] = E[V(\tau(0))] - E[V(\tau(\infty))] + E \left[ \int_0^T \left( \tau^T(t) \tilde{Q}(t) + 2\tau^T(t) \tilde{P}(t) \tilde{P}(t) \right) dt \right] 
\]  
(A7)

www.intechopen.com
By Lemma 2, we have
\[2\mathbb{E}^T(t)P_E\mathbb{E}^T(t) = \mathbb{E}^T(t)P_E\mathbb{E}^T(t) + \mathbb{E}^T(t)E^T(t)P_T(t) \leq \frac{1}{\rho^2} \mathbb{E}^T(t)P_E\mathbb{E}^T(t) + \rho^2 \mathbb{E}^T(t)E(t)E(t)dt\] (A8)

Therefore, we can obtain
\[
E\left[ \int_0^t \mathbb{E}^T(t)E(t)E(t)dt \right] \leq E[V(\mathbb{E}(0))] + E\left[ \int_0^t \left( \mathbb{E}^T(t)P_E\mathbb{E}^T(t) + \sum_{i=1}^L h_i(z(t)) \sum_{j=1}^L k_i(z(t)) \mathbb{E}^T(t)P_i + \rho^2 \mathbb{E}^T(t)E(t)E(t)dt \right) \right] 
+ \frac{1}{\rho^2} \mathbb{E}^T(t)P_E\mathbb{E}^T(t) \mathbb{E}(t)dt
= E[V(\mathbb{E}(0))] + E\left[ \int_0^t \mathbb{E}^T(t)P_E\mathbb{E}^T(t)dt \right] + \rho^2 \mathbb{E}^T(t)E(t)E(t)dt
\]
(A9)

By the inequality in (20), then we get
\[
E\left[ \int_0^t \mathbb{E}^T(t)E(t)E(t)dt \right] \leq E[V(\mathbb{E}(0))] + \rho^2 E\left[ \int_0^t \mathbb{E}^T(t)E(t)E(t)dt \right]
\]
(A10)

This is the inequality in (9). If \( \mathbb{E}(0) = 0 \), then we get the inequality in (8).

### 7.3 Appendix C: Proof of Lemma 1

For \( e_1, e_2, e_3, e_4, e_5, e_6 \neq 0 \), if (25)-(26) hold, then

\[
\begin{bmatrix}
    1 & e_1 & e_2 & e_3 & e_4 & e_5 & e_6 \\
    e_1^T & a_{11} & 0 & 0 & a_{14} & a_{15} & 0 \\
    e_2 & 0 & a_{22} & a_{23} & 0 & 0 & 0 \\
    e_3 & 0 & a_{32} & a_{33} & 0 & a_{36} & 0 \\
    e_4 & a_{41} & 0 & 0 & a_{44} & 0 & 0 \\
    e_5 & a_{51} & 0 & 0 & 0 & a_{55} & 0 \\
    e_6 & 0 & a_{61} & 0 & 0 & a_{66} & 0 \\
\end{bmatrix} = \begin{bmatrix}
    1 & e_1 & e_2 & e_3 & e_4 & e_5 & e_6 \\
    e_1^T & a_{11} & 0 & 0 & a_{14} & a_{15} & 0 \\
    e_2 & 0 & a_{22} & a_{23} & 0 & 0 & 0 \\
    e_3 & 0 & a_{32} & a_{33} & 0 & a_{36} & 0 \\
    e_4 & a_{41} & 0 & 0 & a_{44} & 0 & 0 \\
    e_5 & a_{51} & 0 & 0 & 0 & a_{55} & 0 \\
    e_6 & 0 & a_{61} & 0 & 0 & a_{66} & 0 \\
\end{bmatrix} \begin{bmatrix}
    0 & 0 & 0 & 0 & 0 & 0 & 0 \\
    b_{11} & b_{12} & 0 & 0 & 0 & 0 & 0 \\
    b_{21} & b_{22} & b_{23} & 0 & b_{24} & 0 & 0 \\
    b_{31} & b_{32} & b_{33} & 0 & b_{34} & 0 & 0 \\
    0 & 0 & 0 & 0 & 0 & 0 & 0 \\
    0 & 0 & 0 & 0 & 0 & 0 & 0 \\
    0 & 0 & 0 & 0 & 0 & 0 & 0 \\
\end{bmatrix} 
\]

This implies that (27) holds. Therefore, the proof is completed.
7.4 Appendix D: Parameters of the Fuzzy System, control gains and observer gains
The nonlinear innate immune system in (33) could be approximated by a Takagi-Sugeno Fuzzy system. By the fuzzy modeling method (Takagi & Sugeno, 1985), the matrices of the local linear system \( A_i \), the parameters \( B \), \( C \), \( D \), \( K_j \) and \( L_i \) are calculated as follows:

\[
A_1 = \begin{bmatrix}
0 & 0 & 0 & 0 \\
3 & -1 & 0 & 0 \\
-0.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_2 = \begin{bmatrix}
0 & 0 & 0 & 0 \\
3 & -1 & 0 & 0 \\
-0.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_3 = \begin{bmatrix}
0 & 0 & 0 & 0 \\
3 & -1 & 0 & 0 \\
-0.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_4 = \begin{bmatrix}
-2 & 0 & 0 & 0 \\
9 & -1 & 0 & 0 \\
-1.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_5 = \begin{bmatrix}
-2 & 0 & 0 & 0 \\
9 & -1 & 0 & 0 \\
-1.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_6 = \begin{bmatrix}
-2 & 0 & 0 & 0 \\
9 & -1 & 0 & 0 \\
-1.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_7 = \begin{bmatrix}
-4 & 0 & 0 & 0 \\
15 & -1 & 0 & 0 \\
-2.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_8 = \begin{bmatrix}
-4 & 0 & 0 & 0 \\
15 & -1 & 0 & 0 \\
-2.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},
A_9 = \begin{bmatrix}
-4 & 0 & 0 & 0 \\
15 & -1 & 0 & 0 \\
-2.5 & 1 & -1.5 & 0 \\
0.5 & 0 & 0 & -1
\end{bmatrix},

\[
B = \begin{bmatrix}
-1 & 0 & 0 & 0 \\
0 & -1 & 0 & 0 \\
0 & 0 & 1 & 0 \\
0 & 0 & 0 & -1
\end{bmatrix},
C = \begin{bmatrix}
0 & 1 & 0 & 0 \\
0 & 0 & 1 & 0 \\
0 & 0 & 0 & 1
\end{bmatrix},
D = \begin{bmatrix}
1 & 0 & 0 & 0 \\
0 & 1 & 0 & 0 \\
0 & 0 & 1 & 0 \\
0 & 0 & 0 & 1
\end{bmatrix}.
\]

\[
K_j = \begin{bmatrix}
17.712 & 0.14477 & -0.43397 & 0.18604 \\
0.20163 & 18.201 & 0.37171 & -0.00052926 \\
0.51947 & -0.31484 & 13.967 & -0.052906 \\
0.28847 & 0.0085838 & 0.046538 & 14.392
\end{bmatrix}, \quad j = 1, \ldots, 9.
\]

\[
L_i = \begin{bmatrix}
12.207 & -26.065 & 22.367 \\
93.156 & -8.3701 & 7.8721 \\
-8.3713 & 20.912 & -16.006 \\
7.8708 & -16.005 & 14.335
\end{bmatrix}, \quad i = 1, \ldots, 9.
\]

8. References
Asachenkov, A.L. (1994) Disease dynamics. Birkhäuser Boston.
Balas, G., Chiang, R., Packard, A. & Safonov, M. (2007) MATLAB: Robust Control Toolbox 3: User's Guide. The MathWorks, Inc.
Bell, D.J. & Katusiime, F. (1980) A Time-Optimal Drug Displacement Problem, Optimal Control Applications & Methods, 1, 217-225.
Bellman, R. (1983) *Mathematical methods in medicine*. World Scientific, Singapore.

Bonhoeffer, S., May, R.M., Shaw, G.M. & Nowak, M.A. (1997) Virus dynamics and drug therapy, *Proc. Natl. Acad. Sci. USA*, 94, 6971-6976.

Boyd, S.P. (1994) *Linear matrix inequalities in system and control theory*. Society for Industrial and Applied Mathematics, Philadelphia.

Carson, E.R., Cramp, D.G., Finkelstein, F. & Ingram, D. (1985) Control system concepts and approaches in clinical medicine. In Carson, E.R. & Cramp, D.G. (eds), *Computers and Control in Clinical Medicine*. Plenum Press, New York, 1-26.

Chen, B.S., Chang, C.H. & Chuang, Y.J. (2008) Robust model matching control of immune systems under environmental disturbances: dynamic game approach, *J Theor Biol*, 253, 824-837.

Chen, B.S., Tseng, C.S. & Uang, H.J. (1999) Robustness design of nonlinear dynamic systems via fuzzy linear control, *IEEE Transactions on Fuzzy Systems*, 7, 571-585.

Chen, B.S., Tseng, C.S. & Uang, H.J. (2000) Mixed H-2/H-infinty fuzzy output feedback control design for nonlinear dynamic systems: An LMI approach, *IEEE Transactions on Fuzzy Systems*, 8, 249-265.

Chizeck, H.J. & Katona, P.G. (1985) Closed-loop control. In Carson, E.R. & Cramp, D.G. (eds), *Computers and Control in Clinical Medicine*. Plenum Press, New York, 95-151.

De Boer, R.J. & Boucher, C.A. (1996) Anti-CD4 therapy for AIDS suggested by mathematical models, *Proc. Natl. Acad. Sci. USA*, 94, 6971-6976.

Gentilini, A., Morari, M., Bieniok, C., Wymann, R. & Schnider, T.W. (2001) Closed-loop control of analgesia in humans. *Proc. IEEE Conf. Decision and Control*, Orlando, 861-866.

Janeway, C. (2005) *Immunobiology: the immune system in health and disease*. Garland, New York.

Jang, J.-S.R., Sun, C.-T. & Mizutani, E. (1997) *Neuro-fuzzy and soft computing: a computational approach to learning and machine intelligence*. Prentice Hall, Upper Saddle River, NJ.

Jelliffe, R.W. (1986) Clinical applications of pharmacokinetics and control theory: planning, monitoring, and adjusting regimens of aminoglycosides, lidocaine, digitoxin, and digoxin. In Maronde, R.F. (ed), *Topics in clinical pharmacology and therapeutics*. Springer, New York, 26-82.

Kim, E., Park, M. & Ji, S.W. (1997) A new approach to fuzzy modeling, *IEEE Transactions on Fuzzy Systems*, 5, 328-337.

Kirschner, D., Lenhart, S. & Serbin, S. (1997) Optimal control of the chemotherapy of HIV, *J. Math. Biol.*, 35, 775-792.

Kwong, G.K., Kwok, K.E., Finegan, B.A. & Shah, S.L. (1995) Clinical evaluation of long range adaptive control for mean arterial blood pressure regulation. *Proc. Am. Control Conf.*, Seattle, 786-790.

Li, T.H.S., Chang, S.J. & Tong, W. (2004) Fuzzy target tracking control of autonomous mobile robots by using infrared sensors, *IEEE Transactions on Fuzzy Systems*, 12, 491-501.

Lian, K.Y., Chiu, C.S., Chiang, T.S. & Liu, P. (2001) LMI-based fuzzy chaotic synchronization and communications, *IEEE Transactions on Fuzzy Systems*, 9, 539-553.

Lydyard, P.M., Whelan, A. & Fanger, M.W. (2000) *Instant notes in immunology*. Springer, New York.

www.intechopen.com
Robust $H_\infty$ Tracking Control of Stochastic Innate Immune System Under Noises

Ma, X.J., Sun, Z.Q. & He, Y.Y. (1998) Analysis and design of fuzzy controller and fuzzy observer, *IEEE Transactions on Fuzzy Systems*, 6, 41-51.

Marchuk, G.I. (1983) *Mathematical models in immunology*. Optimization Software, Inc. Worldwide distribution rights by Springer, New York.

Milutinovic, D. & De Boer, R.J. (2007) Process noise: an explanation for the fluctuations in the immune response during acute viral infection, *Biophys J*, 92, 3358-3367.

Nowak, M.A. & May, R.M. (2000) *Virus dynamics: mathematical principles of immunology and virology*. Oxford University Press, Oxford.

Nowak, M.A., May, R.M., Phillips, R.E., Rowland-Jones, S., Laloo, D.G., McAdam, S., Kleneman, P., Koppe, B., Sigmund, K., Bangham, C.R. & et al. (1995) Antigenic oscillations and shifting immunodominance in HIV-1 infections, *Nature*, 375, 606-611.

Parker, R.S., Doyle, J.F., III., Harting, J.E. & Peppas, N.A. (1996) Model predictive control for infusion pump insulin delivery. *Proceedings of the 18th Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. Amsterdam, 1822-1823.

Perelson, A.S., Kirschner, D.E. & De Boer, R. (1993) Dynamics of HIV infection of CD4+ T cells, *Math. Biosci.*, 114, 81-125.

Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, *Science*, 271, 1582-1586.

Piston, D.W. (1999) Imaging living cells and tissues by two-photon excitation microscopy, *Trends Cell Biol*, 9, 66-69.

Polycarpou, M.M. & Conway, J.Y. (1995) Modeling and control of drug delivery systems using adaptive neural control methods. *Proc. Am. Control Conf.*, Seattle, 781-785.

Robinson, D.C. (1986) Topics in clinical pharmacology and therapeutics. In Maronde, R.F. (ed), *Principles of Pharmacokinetics*. Springer, New York, 1-12.

Rundell, A., HogenEsch, H. & DeCarlo, R. (1995) Enhanced modeling of the immune system to incorporate natural killer cells and memory. *Proc. Am. Control Conf.*, Seattle, 255-259.

Schumitzky, A. (1986) Stochastic control of pharmacokinetic systems. In Maronde, R.F. (ed), *Topics in clinical pharmacology and therapeutics*. Springer, New York, 13-25.

Stafford, M.A., Corey, L., Cao, Y., Daar, E.S., Ho, D.D. & Perelson, A.S. (2000) Modeling plasma virus concentration during primary HIV infection, *J. Theor. Biol.*, 203, 285-301.

Stengel, R.F., Ghigliazza, R., Kulkarni, N. & Laplace, O. (2002a) Optimal control of innate immune response, *Optimal Control Applications & Methods*, 23, 91-104.

Stengel, R.F., Ghigliazza, R.M. & Kulkarni, N.V. (2002b) Optimal enhancement of immune response, *Bioinformatics*, 18, 1227-1235.

Sugeno, M. & Kang, G.T. (1988) Structure identification of fuzzy model, *Fuzzy Sets and Systems*, 28, 15-33.

Swan, G.W. (1981) Optimal-Control Applications in Biomedical-Engineering - a Survey, *Optimal Control Applications & Methods*, 2, 311-334.
Takagi, T. & Sugeno, M. (1985) Fuzzy Identification of Systems and Its Applications to Modeling and Control, *IEEE Transactions on Systems Man and Cybernetics*, 15, 116-132.

Tanaka, K., Ikeda, T. & Wang, H.O. (1998) Fuzzy regulators and fuzzy observers: Relaxed stability conditions and LMI-based designs, *IEEE Transactions on Fuzzy Systems*, 6, 250-265.

Tseng, C.S. (2008) A novel approach to H-infinity decentralized fuzzy-observer-based fuzzy control design for nonlinear interconnected systems, *IEEE Transactions on Fuzzy Systems*, 16, 1337-1350.

van Rossum, J.M., Steyger, O., van Uem, T., Binkhorst, G.J. & Maes, R.A.A. (1986) Pharmacokinetics by using mathematical systems dynamics. In Eisenfeld, J. & Witten, M. (eds), *Modelling of biomedical systems*. Elsevier, Amsterdam, 121-126.

Wang, H.O., Tanaka, K. & Griffin, M.F. (1996) An approach to fuzzy control of nonlinear systems: Stability and design issues, *IEEE Transactions on Fuzzy Systems*, 4, 14-23.

Wein, L.M., D’Amato, R.M. & Perelson, A.S. (1998) Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads, *J. Theor. Biol.*, 192, 81-98.

Wiener, N. (1948) *Cybernetics; or, Control and communication in the animal and the machine*. Technology Press, Cambridge.

Wodarz, D. & Nowak, M.A. (1999) Specific therapy regimes could lead to long-term immunological control of HIV, *Proc. Natl. Acad. Sci. USA*, 96, 14464-14469.

Wodarz, D. & Nowak, M.A. (2000) CD8 memory, immunodominance, and antigenic escape, *Eur. J. Immunol.*, 30, 2704-2712.

Zhou, K., Doyle, J.C. & Glover, K. (1996) *Robust and optimal control*. Prentice Hall, Upper Saddle River, N.J.
The main objective of this monograph is to present a broad range of well worked out, recent theoretical and application studies in the field of robust control system analysis and design. The contributions presented here include but are not limited to robust PID, H-infinity, sliding mode, fault tolerant, fuzzy and QFT based control systems. They advance the current progress in the field, and motivate and encourage new ideas and solutions in the robust control area.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Bor-Sen Chen, Chia-Hung Chang and Yung-Jen Chuang (2011). Robust H∞ Tracking Control of Stochastic Innate Immune System Under Noises, Robust Control, Theory and Applications, Prof. Andrzej Bartoszewicz (Ed.), ISBN: 978-953-307-229-6, InTech, Available from: http://www.intechopen.com/books/robust-control-theory-and-applications/robust-h-tracking-control-of-stochastic-innate-immune-system-under-noises

InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 866 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.